bms204352 has been researched along with zoledronic acid in 3 studies
| Studies (bms204352) | Trials (bms204352) | Recent Studies (post-2010) (bms204352) | Studies (zoledronic acid) | Trials (zoledronic acid) | Recent Studies (post-2010) (zoledronic acid) |
|---|---|---|---|---|---|
| 49 | 1 | 12 | 4,108 | 620 | 2,610 |
| Protein | Taxonomy | bms204352 (IC50) | zoledronic acid (IC50) |
|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | 0.316 | |
| Geranylgeranyl pyrophosphate synthase | Homo sapiens (human) | 0.318 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.062 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 7 | |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.2144 | |
| Farnesyl diphosphate synthase | Escherichia coli K-12 | 1.1 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.11 | |
| Geranylgeranyl pyrophosphate synthase | Saccharomyces cerevisiae S288C | 0.424 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 5.323 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
3 other study(ies) available for bms204352 and zoledronic acid
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |